Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029377 · ClinicalTrials.gov registry record · NA
Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT03029377: Completed NA study, sponsored by Vanderbilt University Medical Center.
NCT03029377 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03029377, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
The objective of this study is to measure sympathetic nervous system function and stress responses in patients with clinically documented and self-reported chronic fatigue that is worsened by stress, compared to healthy controls. Baseline norepinephrine (NE) levels and stress-induced NE levels in patients who fulfill criteria for Chronic Fatigue Syndrome (CFS) and who self-identify with stress induced worsening fatigue, will be compared to data from normal individuals pre and post-stress.
Primary Outcome
Change in DHPG/NE Ratio from Baseline to post stress compared across arms
Interventions
- OTHER Posture Study, Autonomic Function Tests, and a Stress Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-02-23 |
| Phase | NA |
What the finished NCT03029377 record still lists
NCT03029377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Posture Study, Autonomic Function Tests, and a Stress Test is the first listed.
NCT03029377 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03029377 about?
NCT03029377 is a clinical study titled "Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome". The objective of this study is to measure sympathetic nervous system function and stress responses in patients with clinically documented and self-reported chronic fatigue that is worsened by stress, compared to healthy controls. Baseline norepinephrine (NE) levels and stress-induced NE levels in pa...
What is the current status of trial NCT03029377?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2017-01. Estimated completion is 2018-02-23.
What interventions are being tested in trial NCT03029377?
The interventions under investigation include: Posture Study, Autonomic Function Tests, and a Stress Test (OTHER).
Who is sponsoring clinical trial NCT03029377?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03029377's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia